

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas D. HORN
Title: IMMUNOTHERAPY OF EPITHELIAL TUMORS USING INTRALESIONAL
INJECTION OF ANTIGENS THAT INDUCE A DELAYED TYPE
HYPERSENSITIVITY REACTION
Appl. No.: unassigned
Filing Date: February 25, 2002
Examiner: unassigned
Art Unit: unassigned

1c971 U.S. PTO
10/081185
02/25/02

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/344,357, filed 06/25/1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

February 25, 2002

By

Richard C. Peet

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5542
Facsimile: (202) 672-5399

Richard C. Peet
Attorney for Applicant
Registration No. 35,792

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.	
(MODIFIED)		PATENT AND TRADEMARK OFFICE		023533/0144		unassigned	
INFORMATION DISCLOSURE CITATION				APPLICANT			
				Thomas HORN, et al.			
Date Submitted to PTO: February 25, 2002				FILING DATE		GROUP ART UNIT	
				February 25, 2002		1642	

10/08/02
 10/08/02
 02/25/02

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,662,903	09/02/1997	BOYER et al.			
	A2	6,123,948	09/26/2000	Whittle et al.			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A3	AMER et al.	"Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts," <i>J. Amer. Acad. Dermatol.</i> , 18(15):1313-6 (1988)				
	A4	BAKER et al.	"Therapeutic Approaches to Papillomavirus Infections," <i>Infectious Diseases in Dermatology</i> , 15(2):331-340 (1997)				
	A5	BOLIN	<i>Equine Disease Quarterly</i> , Vol. 7, No. 3 (April 1999)				
	A6	BRODELL et al.	"The Treatment of Palmar and Plantar Warts Using Natural Alpha Interferon and a Needleless Injector," <i>Dermatol Surg.</i> , 21:213-218 (1995) ©Elsevier Science, Inc.				
	A7	GRIER et al.	"Regression of Cutaneous Melanosarcoma Following Intralesional Mycobacterium bovis BCG Injection: A Case Report," <i>J. of American Animal Hospital Association</i> , 14:76-81 (1978).				
	A8	HORN, Thomas	"Intradermal Skin Testing and Treatment with Candida and Mumps Antigens of Verruca Vulgaris", Dialog Abstract No. 121478 dated June 25, 1998.				
	A9	JOHANSSON et al.	"Dinitrochlorobenzene (DNCB) Treatment of Viral Warts," <i>Acta. Derm Venereol.</i> , 64:529-533 (1984).				
	A10	JOHNSON et al.	"Warts: A Guide to Their Removal," <i>Consultant</i> 39(1):253-266 (1999).				
	A11	KLEIN et al.	"Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial," <i>Cancer Immunol Immunother</i> 21:133-140 (1986) © Springer-Verlag				
	A12	LANDOW, Ken	"Nongenital warts, When is treatment warranted?," <i>Postgraduate Medicine</i> , 99(3):245-249 (1996)				
	A13	MILLER, et al.	"Human Papillomavirus Infection: Treatment Options for Warts," <i>American Family Physician</i> 53(1):135-143 (1996)				
	A14	MILLER et al.	Ophthalmic Surg., Vol. 25, NO. 8, abstract only (1994)				
	A15	MOND et al.	Abstract of WO 95/13089 (1995)				
	A16	NAPLES, et al.	"Verruca Vulgaris: Treatment with Natural Interferon Alfa Using a Needleless Injector," <i>Arch Dermatol.</i> , 129:698-700 (1993)				
	A17	NAYLOR et al.	"Contact Immunotherapy of Resistant Warts," <i>J. Am Acad Dermatol.</i> , 19:679-83 (1988)				
	A18	NELSON, Nancy	"Cancer Vaccines, Disappointing in the Past, Show Promise," <i>J. of the National Cancer Institute</i> , 88(8):486-488 (1996)				
	A19	PFISTER et al.	"Role of HPV in Cutaneous Premalignant and Malignant Tumors," <i>Clinics in Dermatology</i> , 15:335-347 (1997) ©Elsevier Science Inc., New York, New York.				
	A20	QUAN et al.	"The role of human papillomavirus in carcinoma," <i>J. Am Acad Dermatol.</i> , 25(4):698-705 (1991)				

EXAMINER	DATE CONSIDERED
-----------------	------------------------

* **EXAMINER:** Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include any copy of this form with next communication to applicant.